Myeloid 
The susceptibility of cells to induction of apoptosis is regulated by different apoptosis-inducing and apoptosis-suppressing genes (for review, see refs. [1] [2] [3] [4] . We have previously shown that expression of the tumor-suppressing gene wild-type p53 in myeloid leukemic cells induces apoptotic cell death (5) . Wildtype p53 is also involved in certain pathways leading to apoptosis in normal myeloid progenitor cells (6) and normal thymocytes (6) (7) (8) , and there are also wild-type p53-independent pathways for apoptosis (6) (7) (8) (9) . Deregulated expression of c-myc accelerated induction of apoptosis after hematopoietic viability factor deprivation in transfected factor-dependent myeloid cells (10) and after serum deprivation in fibroblasts (11) . The deregulated-c-myc-induced pathway leading to apoptosis in fibroblasts after serum deprivation is mediated by wild-type p53 (12) . We have, however, shown that deregulated expression of c-myc enhanced cell susceptibility to induction of apoptosis by different apoptosis-inducing agents in myeloid leukemic cells without wild-type p53 (13) .
Activation of c-myc can lead to tumor formation (for review, see ref. 14) . Mice constitutively expressing a c-myc transgene driven by the immunoglobulin heavy chain promoter (E,u-myc) develop tumors slowly, suggesting that additional genetic changes must occur and act cooperatively with c-myc to facilitate tumor development (14, 15) . Deregulated expression of c-myc is associated with induction of cell proliferation (14) and inhibition of differentiation (13) and also with increased loss of cell viability by apoptosis under various growth-limiting and cytotoxic conditions in vitro (10, 11, 13) and in E,u-myc mice in vivo (16) . Promotion of viability in cells with deregulated c-myc would allow expression of these other properties of c-myc associated with malignant transformation (1, 2, 13) . Constitutive coexpression of the apoptosis-suppressing gene bcl-2 and deregulated c-myc promoted cell viability (17, 18) and, thus, enhanced tumor formation compared to cells expressing only deregulated c-myc (15, 19) .
Wild-type p53 functions as a tumor-suppressor gene (20, 21) , and knocking out both alleles (p53 -/-) resulted in spontaneous tumor formation (22) . Tumor formation also occurred in heterozygous p53 knock-out mice (p53 + /-) but at a slower rate than in nullizygous p53 (-/-) mice (22 (26) or with both mutant p53 and deregulated c-myc (M1-t-p53-c-myc) (27) . p53 did not change the expression of deregulated c-myc (27 (Northern blot analysis). Cytoplasmic RNAs from Ml-neo, Ml-t-cmyc, M1-t-p53, and M1-t-p53-c-myc myeloid leukemic cells were hybridized with probes for mouse p53 and cytoplasmic 83-actin (to determine RNA loading). (Fig. 1) or protein (5) , whereas the M1-t-p53 and M1-t-p53-c-myc clones constitutively express a 1.8-kb transcript of the mouse [Val135]p53 transgene ( Fig. 1 ) and p53 protein (5) , which at 37°C is in a mutant form (28) . When these Ml clones were seeded in agar to determine their cloning efficiency, all four clones gave a similar number of colonies (Table 1) , and there was no apparent difference in the size of the colonies 7 days after seeding. This indicates that the cloning efficiency and colony size of these Ml clones in vitro were not significantly different. When seeded at 2.5 x 105 cells per ml in suspension culture, cells from all four Ml clones showed a similar growth curve reaching a high cell density of 3.5 x 106 cells per ml (Fig. 2) . Starting on the third to fourth day in culture, there was a decrease in the percent of viable cells in all the clones due to cell death but this decrease was strongest in M1-t-c-myc cells. The percent viability at 5 days in cultures of M1-neo, M1-t-p53, and M1-t-c-myc cells as determined by trypan blue exclusion was 62 ± 5%, 61 + 7%, and cally significant (n = 3; P < 0.01). These 5-day cultures also contained cells with typical apoptotic morphology (small size, condensed chromatin, and fragmented nuclei) and DNA laddering.
The results indicate that expression of the [Val135]p53 mutant by itself in Ml cells did not offer any protection against apoptotic cell death at high cell density in culture. The results also show that deregulated expression of c-myc in Ml leukemic cells was associated with an enhanced loss of viability at high cell density and this effect of deregulated c-myc was partially inhibited by coexpression of the mutant p53. Deregulated expression of c-myc but not of this mutant p53 in Ml cells also showed a higher cell susceptibility to induction of apoptosis by 14) 0 E ._ ._ ., z various cytotoxic agents (13) including cycloheximide (Fig. 3) , and coexpression of this mutant p53 and deregulated c-myc inhibited this enhancing effect of deregulated c-myc on apoptosis induced by a cytotoxic agent.
Effect of Mutant p53 and Deregulated c-myc Expression on Leukemogenicity in Vivo. The four clones of Ml myeloid leukemic cells caused leukemia when injected into isologous mice. The median survival time of 15 mice injected intraperitoneally with M1-t-p53 cells was similar to mice injected with M1-neo cells (43 days and 46 days, respectively) (Fig. 4) . However, the median survival time of 15 mice injected with M1-t-c-myc cells was longer (60 days) than mice injected with M1-neo or M1-t-p53 cells, and coexpression of the mutant p53 and deregulated c-myc (M1-t-p53-c-myc) with a median survival time of 40 days suppressed this increased survival produced by deregulated c-myc. Analysis of three experiments (five mice in each group) showed that the median survival time of mice inoculated with M1-t-c-myc leukemic cells (59.3 ± 4.0 days) was significantly longer than in mice inoculated with M1-neo (P = 0.025), M1-t-p53 (P < 0.02), and M1-t-pS3-c-myc cells (P < 0.01) (45.3 + 5.7, 42.7 ± 5.0, and 41.3 ± 3.2 days, respectively). Two of the 15 mice injected with M1-t-c-myc leukemic cells survived beyond 140 days without apparent signs of leukemia-associated morbidity, whereas none of the mice injected with the other leukemic clones survived beyond 113 days. Intravenous injection of these leukemic clones (10 mice per clone) showed that the median survival time of mice injected with M1-neo, M1-t-p53, M1-t-p53-c-myc, and M1-tc-myc cells was 42, 40, 39, and 54 days, respectively (Fig. 5) . The results obtained with intravenous injection of the leukemic clones were thus similar to those obtained with intraperitoneally injected mice.
DISCUSSION
Mutant p53 (20) and deregulated c-myc (30) are frequently found in human cancers. It has been shown that deregulated expression of c-myc even in p53-negative Ml myeloid leukemic cells can lead to an enhanced susceptibility to induction of apoptosis by various cytotoxic agents including anticancer drugs (13) . We now show that these leukemic cells with deregulated c-myc are also more susceptible to apoptotic cell death under stress conditions of high cell density in culture. Deregulated expression of c-myc in an interleukin 3-dependent myeloid cell line was also shown to cause enhanced apoptosis at a high cell density even in the presence of interleukin 3 (31) . In addition to enhancing apoptosis, deregulated c-myc can induce cell proliferation (14) and inhibit differentiation (13) . Expression of the [Val'35]p53 mutant in myeloid leukemic cells with deregulated c-myc suppressed the enhancing effect of deregulated c-myc on susceptibility to induction of apoptosis without suppressing the inhibitory effect of deregulated c-myc on cell differentiation (13) . This indicates that this mutant p53 could abrogate some but not all c-myc-mediated biological effects. The inhibition of apoptosis by mutant p53 can allow expression of the other properties induced by deregulated c-myc that are associated with malignancy (1, 2, 13). The inhibition of apoptosis by mutant p53 can explain the high frequency of mutant p53 in many types of tumors (32) and the association between p53 mutations and resistance to chemotherapy in human hematological malignancies (33 (24, 25) . Our present results are in agreement with those of others (24, 25) 
